Esophagitis, Gastroenteritis and Misc. Digestive Disorders DRG Reimbursement

DRG 391 encompasses esophagitis, gastroenteritis and miscellaneous digestive disorders with a Major Complication or Comorbidity, reflecting higher clinical complexity and resource needs. This Diagnosis-Related Group matters for inpatient reimbursement because the Major Complication or Comorbidity designation increases payment to account for greater expected costs of care under Medicare.

DRG 391 Overview

DRG 391 covers hospital admissions for esophagitis, gastroenteritis and miscellaneous digestive disorders with Major Complication or Comorbidity. These cases typically involve significant clinical complexity, such as severe dehydration, bleeding, or sepsis, that increases resource use during the inpatient stay. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity adjusts reimbursement to reflect higher expected costs. Accurate documentation and coding of the Major Complication or Comorbidity affect assignment to this Diagnosis-Related Group and associated inpatient payment.

Acute management randomized or pragmatic trials evaluating early inpatient interventions for severe esophagitis, acute gastroenteritis with dehydration, or other complicated digestive disorders (for example, protocols comparing different fluid resuscitation strategies, timing of endoscopic evaluation, or adjunctive supportive measures). These studies enroll hospitalized adults or children presenting with acute inflammatory or infectious digestive conditions complicated by hemodynamic instability, bleeding, or severe electrolyte disturbances. Results inform clinicians and hospitalists about optimal in-hospital care pathways that can reduce ICU transfers, length of stay, and avoid escalation to more costly treatments — metrics directly relevant to inpatient reimbursement and resource allocation for DRG 391 cases.
Comparative effectiveness studies of diagnostic and procedural strategies for complicated upper and lower digestive tract conditions, such as trials comparing immediate versus delayed endoscopy, different biopsy or imaging protocols, or minimally invasive versus standard endoscopic approaches in patients with esophagitis-related strictures or complicated gastroenteritis complications. These studies target heterogeneous inpatients with comorbidities who trigger MCC assignment and aim to determine which diagnostic or procedural choices lead to better short-term outcomes, fewer complications, and lower rates of readmission. Findings guide clinicians and payers on cost-effective use of hospital procedures and help refine case-mix adjustments and bundled-payment expectations for high-acuity DRG 391 admissions.
Post-discharge outcomes and care-transition cohort studies assessing readmission risk, functional recovery, nutritional status, and outpatient resource use after hospitalization for severe digestive disorders with complications. These observational studies follow patients after discharge from the index DRG 391 admission to identify predictors of costly readmissions, durable complications (like strictures or chronic malabsorption), and the impact of post-acute services (nutrition support, outpatient GI follow-up) on long-term outcomes. Such evidence helps hospitals, payers, and care managers design discharge planning, targeted post-acute interventions, and quality metrics to reduce preventable readmissions and downstream costs associated with this high-acuity DRG.

Acute management randomized or pragmatic trials evaluating early inpatient interventions for severe esophagitis, acute gastroenteritis with dehydration, or other complicated digestive disorders (for example, protocols comparing different fluid resuscitation strategies, timing of endoscopic evaluation, or adjunctive supportive measures). These studies enroll hospitalized adults or children presenting with acute inflammatory or infectious digestive conditions complicated by hemodynamic instability, bleeding, or severe electrolyte disturbances. Results inform clinicians and hospitalists about optimal in-hospital care pathways that can reduce ICU transfers, length of stay, and avoid escalation to more costly treatments — metrics directly relevant to inpatient reimbursement and resource allocation for DRG 391 cases.
Comparative effectiveness studies of diagnostic and procedural strategies for complicated upper and lower digestive tract conditions, such as trials comparing immediate versus delayed endoscopy, different biopsy or imaging protocols, or minimally invasive versus standard endoscopic approaches in patients with esophagitis-related strictures or complicated gastroenteritis complications. These studies target heterogeneous inpatients with comorbidities who trigger MCC assignment and aim to determine which diagnostic or procedural choices lead to better short-term outcomes, fewer complications, and lower rates of readmission. Findings guide clinicians and payers on cost-effective use of hospital procedures and help refine case-mix adjustments and bundled-payment expectations for high-acuity DRG 391 admissions.
Post-discharge outcomes and care-transition cohort studies assessing readmission risk, functional recovery, nutritional status, and outpatient resource use after hospitalization for severe digestive disorders with complications. These observational studies follow patients after discharge from the index DRG 391 admission to identify predictors of costly readmissions, durable complications (like strictures or chronic malabsorption), and the impact of post-acute services (nutrition support, outpatient GI follow-up) on long-term outcomes. Such evidence helps hospitals, payers, and care managers design discharge planning, targeted post-acute interventions, and quality metrics to reduce preventable readmissions and downstream costs associated with this high-acuity DRG.

OpenPayer

Summary & Overview

Esophagitis, Gastroenteritis and Miscellaneous Digestive Disorders with MCC: Inpatient Reimbursement Overview

DRG 391 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes